Deutsch English Français

Contact

EP3221298

European procedure

Quick help

Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...

News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...

Extract from the Register of European Patents

EP About this file: EP3221298

EP3221298 - 4-OXO-3,4-DIHYDRO-1,2,3-BENZOTRIAZINE DERIVATIVES AS MODULATORS OF GPR139 [Right-click to bookmark this link]
Former [2017/39]	4-OXO-3,4-DIHYDRO-1,2,3-BENZOTRIAZINES AS MODULATORS OF GPR139
	[2018/43]
Status	No opposition filed within time limit Status updated on 07.02.2020 Database last updated on 08.10.2024
Former	The patent has been granted Status updated on 01.03.2019
Former	Grant of patent is intended Status updated on 20.02.2019
Former	Examination is in progress Status updated on 07.02.2019
Former	Grant of patent is intended Status updated on 04.10.2018
Former	Examination is in progress Status updated on 08.06.2018
Former	Request for examination was made Status updated on 25.08.2017
Former	The international publication has been made Status updated on 02.06.2017
Most recent event Tooltip	07.02.2020	No opposition filed within time limit	published on 11.03.2020 [2020/11]
Applicant(s)	For all designated states Takeda Pharmaceutical Company Limited 1-1 Doshomachi 4-chome Chuo-ku Osaka-shi, Osaka 541-0045 / JP
	[2017/39]
Inventor(s)	01 / HITCHCOCK, Stephen c/o Takeda California, Inc. 10410 Science Center Drive San Diego, California 92121 / US
	02 / LAM, Betty c/o Takeda California, Inc. 10410 Science Center Drive San Diego, California 92121 / US
	03 / MONENSCHEIN, Holger c/o Takeda California, Inc. 10410 Science Center Drive San Diego, California 92121 / US
	04 / REICHARD, Holly c/o Takeda California, Inc. 10410 Science Center Drive San Diego, California 92121 / US
	[2019/14]
Former [2017/39]	01 / HITCHCOCK, Stephen c/o Takeda California, Inc. 10410 Science Center Drive San Diego, California 92121 / US
	02 / LAM, Betty c/o Takeda California Inc. 10410 Science Center Drive San Diego, California 92121 / US
	03 / MONENSCHEIN, Holger c/o Takeda California Inc. 10410 Science Center Drive San Diego, California 92121 / US
	04 / REICHARD, Holly c/o Takeda California Inc. 10410 Science Center Drive San Diego, California 92121 / US
Representative(s)	D Young & Co LLP 3 Noble Street London EC2V 7BQ / GB
	[N/P]
Former [2017/39]	D Young & Co LLP 120 Holborn London EC1N 2DY / GB
Application number, filing date	15816275.0	19.11.2015
	[2017/39]
	WO2015US61607
Priority number, date	US201462082539P	20.11.2014 Original published format: US 201462082539 P
	US201562184729P	25.06.2015 Original published format: US 201562184729 P
	[2017/39]
Filing language	EN
Procedural language	EN
Publication	Type:	A1 Application with search report
	No.:	WO2016081736
	Date:	26.05.2016
	Language:	EN
	[2016/21]
	Type:	A1 Application with search report
	No.:	EP3221298
	Date:	27.09.2017
	Language:	EN
	The application published by WIPO in one of the EPO official languages on 26.05.2016 takes the place of the publication of the European patent application.
	[2017/39]
	Type:	B1 Patent specification
	No.:	EP3221298
	Date:	03.04.2019
	Language:	EN
	[2019/14]
Search report(s)	International search report - published on:	EP	26.05.2016
Classification	IPC:	C07D253/08, A61K31/53	[2017/39]
	CPC:	A61P3/04 (EP); C07D253/08 (EP,CN,EA,IL,US); C07D235/08 (EA,KR); A61K31/53 (EA,IL,KR,US); A61P21/00 (EP); A61P25/00 (EP); (+) A61P25/04 (EP); A61P25/18 (EP,EA,US); A61P25/20 (EP); A61P25/22 (EP); A61P25/24 (EP); A61P25/28 (EP); A61P25/30 (EP); A61P43/00 (EP) (-)
Designated contracting states	AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2017/39]
Extension states	BA	20.06.2017
	ME	20.06.2017
Validation states	MA	20.06.2017
	MD	20.06.2017
Title	German:	4-OXO-3,4-DIHYDRO-1,2,3-BENZOTRIAZINDERIVATE ALS GPR139-MODULATOREN	[2018/43]
	English:	4-OXO-3,4-DIHYDRO-1,2,3-BENZOTRIAZINE DERIVATIVES AS MODULATORS OF GPR139	[2018/43]
	French:	DÉRIVÉS DE 4-OXO-3,4-DIHYDRO-1,2,3-BENZOTRIAZINE COMME MODULATEURS GPR139	[2018/43]
	Former [2017/39]	4-OXO-3,4-DIHYDRO-1,2,3-BENZOTRIAZINE ALS MODULATOREN VON GPR139
	Former [2017/39]	4-OXO-3,4-DIHYDRO-1,2,3-BENZOTRIAZINES AS MODULATORS OF GPR139
	Former [2017/39]	4-OXO-3,4-DIHYDRO-1,2,3-BENZOTRIAZINES UTILISÉES EN TANT QUE MODULATEURS DE GPR139
Entry into regional phase	20.06.2017	National basic fee paid
	20.06.2017	Designation fee(s) paid
	20.06.2017	Examination fee paid
Examination procedure	01.06.2017	Date on which the examining division has become responsible
	20.06.2017	Examination requested [2017/39]
	19.12.2017	Amendment by applicant (claims and/or description)
	07.06.2018	Despatch of a communication from the examining division (Time limit: M04)
	14.09.2018	Reply to a communication from the examining division
	05.10.2018	Communication of intention to grant the patent
	05.02.2019	Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
	05.02.2019	Fee for grant paid
	05.02.2019	Fee for publishing/printing paid
	20.02.2019	Information about intention to grant a patent
	20.02.2019	Receipt of the translation of the claim(s)
Divisional application(s)	EP19152036.0 / EP3536324
Opposition(s)	06.01.2020	No opposition filed within time limit [2020/11]
Fees paid	Renewal fee
	27.11.2017	Renewal fee patent year 03
	27.11.2018	Renewal fee patent year 04
Opt-out from the exclusive Tooltip competence of the Unified Patent Court	See the Register of the Unified Patent Court for opt-out data
	Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Cited in	International search	[A]US3794726 (ARIYAN Z) [A] 1-37 * column 1 - column 2; claims 1-11 *;
		[A]US4959367 (KING FRANCIS D [GB]) [A] 1-37 * column 8, line 10 - line 19; claims 1-10 *;
		US2009163545 [ ] (GOLDFARB DAVID SCOTT [US]);
		[X] - REGISTRY, CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US, (20080824), Database accession no. 1043204-06-3, URL: STN, XP002754167 [X] 19 * Cas Registry Numbers 1043204-06-3, 1314016-24-4, 4403331-93-1, 440332-03-6, 929825-97-8, 919725-54-5, 440331-96-4, 1001630-69-8 *
		[X] - REGISTRY, CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US, (20140326), Database accession no. 1574302-61-6, URL: STN, XP002754168 [X] 19 * CAS Registry Numbers 1574302-61-6, 1314016-24-4, 440332-03-6, 1144497-15-3, 440331-97-5, 1314016-16-4, 1002792-66-6, 1314014-40-8, 919725-54-5, 1043204-06-3, 929825-97-8, 1043286-27-6, 942888-50-8, 440331-93-1, 440331-97-5, 440331-96-4, 1314014-56-6, 440331-94-2, 1235321-41-1, 440332-02-5, 1097448-92-4, 440332-01-4, 942888-62-2, 1001630-69-8, *
		[X] - REGISTRY, CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US, (20100804), Database accession no. 1234906-37-6, URL: STN, XP002754169 [X] 19 * CAS Registry Numbers 1234906-37-6, 440332-03-6, 1234899-71-8, 1235008-33-9, 1235047-78-5, 1234815-58-7, 1235671-40-5, 1235355-81-3, 1235150-10-3, 1235069-04-1, 1235107-91-1, 1235321-41-1, 1235660-88-4, 1234789-40-2, 1234810-92-4, 1323657-53-9, 1234901-31-5, 1235344-79-2, 1235085-25-2, 1235658-52-2, 1235299-63-4, 1235636-90-4, 1235058-83-9, 1235052-93-3 *
		[X] - GOLDFARB, DAVID SCOTT, "Method using lifespan-altering compounds for altering the lifespan of eukaryotic organisms, and screening for such compounds", CA, CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US, (2009), Database accession no. 2009:846113, URL: STN, XP002754170 [X] 19 * RN: 440332-01-4, 785799-50-0, 78561-07-3, 784168-58-7 *
		[AD] - FENG SHI ET AL, "Discovery and SAR of a Series of Agonists at Orphan G Protein-Coupled Receptor 139", ACS MEDICINAL CHEMISTRY LETTERS, (20110414), vol. 2, no. 4, doi:10.1021/ml100293q, ISSN 1948-5875, pages 303 - 306, XP055124814 [AD] 35-37 * the whole document * DOI: http://dx.doi.org/10.1021/ml100293q
	by applicant	WO2014152917
		- J. CHEM. INF. MODEL, (2014), vol. 54, pages 1553 - 1557
		- MED. CHEM. LETT, (2011), vol. 2, pages 303 - 306
		- JOURNAL OF PHARMACEUTICAL SCIENCE, (1977), vol. 66, pages 2 - 19

The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.

Legal notice
Terms of use
24.2.25; 35p